reports
Natco Pharma Limited: 1 director
A director at Natco Pharma Limited sold 1,500 shares at 1,617.570INR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
With a more favourable environment, NATCO PHARMA improves to Slightly ...
NATCO PHARMA (IN), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 17, 2021, the closing price was INR 843.80 and its potenti...
- Nitin Agarwal
Natco Pharma's Q3FY20 results (Outperformer) - Soft quarter
Q3FY20 result highlights Consol revs came at Rs4.8bn vs est Rs5bn; 13% decline yoy. Yoy numbers are not comparable due to significant share of gTamiflu sales in the base Exports sales came at Rs1.9bn below est of Rs2.2bn; Q2 was Rs2.25bn – mgt cited higher material supplies in Q2 and expects higher gTamiflu profit share in Q4 Domestic formulations sharply stood at Rs1.5bn vs est Rs1.35bn (7% decline) due to lower HepC and CnD sales. Oncology sales flat yoy EBITDA came at Rs1.3bn vs est Rs1...
- Nitin Agarwal
Natco Pharma's Q2FY20 results (Outperformer) - Soft quarter; Domestic ...
Q2FY20 result highlights Consol revs came at Rs4.9bn vs est Rs5.3bn; yoy numbers are not comparable due to significant share of gTamiflu sales in the base Exports sales came at Rs2.2bn inline with est; Q1 was Rs2.1bn – gCopaxone and gDoxil continue to be the primary driver Domestic formulations sharply declined (-26% qoq) to Rs1.2bn vs est Rs1.8bn due to lower oncology and CnD sales. HepC sales flat qoq EBITDA came at Rs1.3bn vs est Rs2bn; Q1 was Rs1.9bn. EBITDAM at 27.7% vs est 37.1% main...
- Nitin Agarwal
Event update: Natco Pharma (Outperformer) - Initiates agrochem foray; ...
Event Natco has announced that it has developed a technical product for Chlorantraniliprole (CTPR) – a broad spectrum insecticide used in several crops Key highlights Natco has developed a technical product for CTPR and hopes to bring affordable formulations based on this technical product. It has filed for/ is awaiting technical approval for its CTPR product Notably, CTPR is an AI which is used in FMC brands Coragen / Ferterra which combined sales of >Rs15bn in India (as per 2016 declara...
- Nitin Agarwal
Company update: Natco Pharma (Outperformer) - Non US businesses to dri...
This note highlights drivers for Natco’s ex-US business segments, as derived from Natco Pharma’s recent FY19 Annual Report. Management has indicated that a strong pickup in non-US business segments would drive growth over the next couple of years, given the lack of new meaningful launches in the US over FY19-21. Non-US business – growing in salience: While US generics has been Natco’s primary growth driver over last few years, the company has been striving to increase the salience of its non-U...
- Nitin Agarwal
Natco Pharma's Q1FY20 results (Outperformer) - Good quarter; US busine...
Q1FY20 result highlights Consol revs came at Rs4.9bn vs est Rs5bn; yoy nos are not comparable due to significant share of gTamiflu sales in the base Exports sales came at Rs2.1bn vs est Rs1.7bn; Q4 was Rs1.4bn – due to a higher-than-expected contribution from gCopaxone Domestic sales declined +13% yoy to Rs1.64bn vs est Rs2bn due to lower HepC sales (Rs310m vs Rs420m in Q4) and soft oncology sales. EBITDA came at Rs1.9bn vs est Rs1.5bn; Q4 was Rs1.5bn. EBITDAM at 38.9% vs est 30.4% aided b...
- Nitin Agarwal
Natco Pharma's Q4FY19 results (Outperformer) - Soft quarter; Strong gr...
Q4FY19 result highlights Consol revs came at Rs4.6bn vs est Rs5.2bn; yoy nos are not comparable due to significant share of gTamiflu sales in the base Exports sales came at Rs1.44bn vs est Rs1.99bn; Q3 was Rs2.57bn – Q3 had significantly higher profit share from gTamiflu in Q3 Domestic sales grew +19% yoy to Rs1.88bn vs est Rs1.75bn due to strong growth in oncology sales. API was Rs700m vs est Rs900m; EBITDA came at Rs1.48bn vs est Rs1.9bn; Q3 was Rs2bn. GMs were strong but profits were im...
- Nitin Agarwal
NATCO Pharma's Q3FY19 results (Outperformer) - Steady quarter; lowers ...
Q3FY19 result highlights Consol Revs came at Rs5.56bn vs est Rs5.1bn; Q2 was Rs5.43bn. Domestic revs came at Rs1.64bn vs est Rs2bn; flat yoy; Q2 was Rs1.94bn. Formulation exports (incl profit share) was Rs2.57bn – flat yoy; est Rs2.4bn. Key contributor likely to be profit share on key drugs including gCopaxone, gTamiflu, gDoxil etc API was Rs990m vs est Rs700m; Foreign subs revs were Rs250m EBITDA came at Rs2.08bn vs est Rs1.8bn; Q2 was Rs2.2bn. GMs as well as overheads were broadly in lin...
- Nitin Agarwal
Event update: Natco Pharma (Outperformer) - Another blockbuster FTF A...
Event Natco Pharma has announced that, in partnership with Alvogen, it has filed the P-IV challenge on Ibtrutinib tablets (brand name – Imbruvica) across all strengths – 140mg, 280mg, 420mg and 560mg Key Highlights Notably, while multiple players have filed P-IV ANDA challenge for Imbruvica capsules and have shared exclusivity for the same, Natco- Alvogen have been the first and likely only to file the P-IV challenge on the much bigger Imbruvica tablet formulation in Nov / Dec 2018. This s...
- Nitin Agarwal
Event update: Natco Pharma (Outperformer) - Strategic innovation conti...
Event Over the last few days, Natco has made a couple of announcements which are interesting from a strategic perspective even though the near term financial impact may be limited Key highlights Launch of generic Valsartan / Sacubitril tablets - generic version of Novartis’ relatively new cardiac drug Ernesto – in India Management has indicated that currently Novartis sells the drug on its own as well as through a couple of partners; current sales are >Rs1bn. There are a couple of patents ...
- Nitin Agarwal
NATCO Pharma's Q1FY19 results (Outperformer) - Below estimates led by ...
Q1FY19 result highlights Natco reported lower sales of Rs5.4b (-21%/30% yoy/qoq) vs est of Rs6.5b led by lower profit share of Rs2.1bn (Rs4.33bn in Q4) vs our est of Rs3.3bn. Mgmt indicated that a reasonable amount of profit share has been deferred and will be booked in Q2 Led by lower revenues Natco reported lower EBITDA of Rs2.2bn (-43% qoq) vs our est of Rs3.06bn. EBITDA margin came in lower at 40.4% (vs 49.9% in Q4) vs est of 47.1%. GMs stood better at 83.8% (vs est 82.5%). Employee exp...
- Nitin Agarwal
NATCO Pharma's Q4FY18 results (Outperformer) - Inline quarter; non-US ...
Q4FY18 result highlights Natco reported sales of Rs7.7b (+33%/37% yoy/qoq) vs est of Rs7.5b driven by higher profit share of Rs4.33bn (vs Rs2.54bn in Q3) from products like gCopaxone, gTamiflu along with gDoxil and gFosrenol. Natco reported EBITDA of Rs3.8bn (+59%/34% yoy/qoq) inline with our est of Rs3.8bn. EBITDA margin came in lower at 49.9% (vs 51% in Q3) vs est of 51.1%. GMs stood better at 84% (vs est 79.3%) due to higher profit share component. Employee expenses came higher at Rs1.1b...
- Nitin Agarwal
NATCO Pharma's Q3FY18 results (Outperformer) - Strong quarter; Q4 to b...
Q3FY18 result highlights Natco reported sales of Rs5.6b (down 17% yoy / +32% qoq) below our est of Rs5.8b. Domestic formulation revenues stood lower at Rs1.65bn (-24% yoy). API grew +60% yoy to Rs810m. Natco reported EBITDA of Rs2.9bn (+10%/135% yoy/qoq) vs est of Rs2.7bn. EBITDA margin came at 51% vs est of 46.4%. GMs stood significantly higher at 88.3% (vs 73.5% in Q2FY18) ahead of est 76% driven by higher profit share of Rs2.5bn accruing from gTamiflu and gCopaxone during the quarter. E...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.